| ADC | antibody drug conjugate |
| AKTi | AKT inhibitor |
| ANOVA | analysis of variance |
| ATCC | American Type Culture Collection |
| DMEM | Dulbecco’s modified Eagle’s medium |
| DMSO | dimethyl sulfoxide |
| DNMT1 | DNA (cytosine-5)-methyltransferase 1 |
| DPBS | Dulbecco’s phosphate buffered saline |
| EGFR | epidermal growth factor receptor |
| ER | estrogen receptor |
| ERK | extracellular signal-regulated kinase |
| FBS | fetal bovine serum |
| FDA | Food and Drug Administration |
| FLT3 | FMS-like tyrosine kinase 3 |
| GvHD | graft-versus-host disease |
| HER2 | human epidermal growth factor 2 |
| IL6 | interleukin 6 |
| JAK | Janus kinase |
| JAK2i | JAK2 inhibitor |
| MEK | MAP kinase/ERK kinase |
| MEKi | MEK inhibitor |
| mTOR | mammalian target of rapamycin |
| MTT | 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide |
| PARP1 | poly [adenosine diphosphate (ADP)-ribose] polymerase 1 |
| PD-L1 | programmed cell death ligand 1 |
| PDLIM4 | PDZ and LIM domain protein 4 |
| PKI | protein kinase inhibitor |
| PR | progesterone receptor |
| PVDF | polyvinylidene difluoride |
| RET | rearranged during transfection |
| RTK | receptor tyrosine kinase |
| STAT3 | signal transducer and activator of transcription 3 |
| SYK | spleen tyrosine kinase |
| TNBC | triple-negative breast cancer |
| TYK2 | tyrosine kinase 2 |
| VHL | von Hippel-Lindau disease tumor suppressor |
| XIAP | X-linked inhibitor of apoptosis protein |